Medicines: Public confusion as to medical confusion?

Chemicals or the rearrangement of atoms comprise everything on Earth and as Humans we are very succeptable to chemical imbalance given the chemicals in the food that we consume and the polluted air that we breath but Chemical Medicines in themselves can create imbalances too if they do not address the imbalance source. Of course the power of ones mind can also alter ones metabolism should the Social environment not be conducive to Healthy Standards of living thus leading to low moral, anxiety and depression. Nevertheless most of our current day ills are treated by pharmaceutical Companies whom provide Medicines for database entry allowing Doctors go digital shopping on behalf of their patients. “Try these” a Doctor may say in swopping one prescribed medication for another in a 5 minute consultation but what medicines are safe?. Whom has tested them?. There are also Trademark and licencing issues to contend with along with PIL’s [ Patient information leaflets ] which accompany medicines as to conveying the correct information. Are Patients fully aware of which Regulatory Authority to complain to if adverse affects result from a prescribed medication or is it that Doctors only should appraise such Authority themselves given that they may have themselves prescribed the wrong medication to a patient in the first place!. 

 

There exists the Medicines Control Agency [ MCA ], The British National Formulary ( BNF ) and the Medicines and Healthcare products Regulatory Agency (MHRA) formed in April 2003. The latter [ MHRA ] is responsible for ensuring that medicines are acceptably safe whereas the BNF provides prescribers, pharmacists and other healthcare professionals with information about the use of medicines including their selection, prescribing, dispensing and administration. The BNF can construct new non-proprietary names for medicinal products where the patent of an existing proprietary product has expired (or about to) OR where a new generic formulation having the same composition as a proprietary product has been introduced. According to the 1968 Medicines Act –UK, Some preparations which are not prescribable by brand name under the NHS may nevertheless be dispensed using the brand name providing that the prescription shows an appropriate non-proprietary name – ie: A DIFFERENT NAME!. 

 

Consider Diazepam having the Molecular Formula: C16H13ClN2O. It has the following Synonyms: (Total: 285): Diazepam; Valium; Ansiolisina; Methyldiazepinone; Calmocitene; Neurolytril; Bialzepam; Ceregulart; Condition; Diazemuls; Diazetard; Liberetas; Relaminal; Serenamin; Tranquirit; Ansiolin; Apozepam; Atensine; Bensedin; Calmpose; Diacepan; Diazepan; Dipezona; Domalium; Kiatrium; Paranten; Quetinil; Quiatril; Quievita; Relanium; Renborin; Ruhsitus; Seduksen; Serenack; Serenzin; Stesolid; Stesolin; Tensopam; Tranimul; Tranqdyn; Unisedil; Valitran; Alboral; Aliseum; Amiprol; Apaurin; Armonil; Assival; Cercine; Diastat; Dienpax; Eurosan; Faustan; Freudal; Frustan; Gihitan; Horizon; Lembrol; Morosan; Saromet; Sedipam; Seduxen; Setonil; Sibazon; Sonacon; Umbrium; Atilen; Dialag; Diapam; Duksen; Eridan; Levium; Paxate; Plidan; Vatran; Velium; Duxen; Lamra; Paxel; Relax; Solis; Valeo; Vival; Vivol; Zipan; Noan; Usempax ap; Azedipamin; Britazepam; Calmociteno; Centrazepam; Kabivitrum; Ortopsique; Valrelease; Ansilive; Anxicalm; Anxionil; Benzopin; Calmaven; Chuansuan; Desconet; Desloneg; Diaceplex; Diazepin; Gewacalm; Jinpanfan; Mentalium; Metamidol; Nixtensyn; Novodipam; Pacitran; Paralium; Prozepam; Psychopax; Radizepam; Simasedan; Trankinon; Trazepam; Valaxona; Valiquid; Valuzepam; Vanconin; Antenex; Arzepam; Betapam; Diapine; Diaquel; Diatran; Disopam; Drenian; Evacalm; Faustal; Gradual; Iazepam; Kratium; Medipam; Nellium; Nerozen; Nervium; Nivalen; Notense; Novazam; Reliver; Zepaxid; Baogin; Calmod; Caudel; Dialar; Diapax; Diazem; Ducene; Lovium; Mandro; Paceum; Parzam; Dipam; Dipaz; Dizac; Doval; Dupin; Gubex; Lizan; Paxum; Pomin; Sipam; Vazen; Winii; Best; Apo-diazepam; Diazepam Nordic; Diazepam-Lipuro; Diazepan leo; Methyl diazepinone; Diazepam Fabra; Diazepam Stada; Diazepam Elmu; Metil Gobanal; Diazepam Dak; e-Pam; Diazepam Desitin; Euphorin P; Mandro-Zep; Sico Relax; Diazapam; Tranquase; Alupram; Sedapam; Tensium; Vazepam; Diazepam Rectubes; neurolytr il; Placidox 2; Placidox 5; Elcion CR; An-Ding; Kratium 2; ProPAM; Tranquo-tablinen; Diazepam-ratiopharm; Faustan,; Placidox 10; Diazepam solution; Diazepam Intensol; Valium R; D-Pam; Diazepamu [Polish]; T-quil; Diazepam-Eurogenerics; Q-pam; LA III; La-Iii; Diastat (TN); Valium (TN); Diazepamum [INN-Latin]; nchembio747-comp27; Spectrum3_001780; Spectrum4_000576; Spectrum5_001890; S.a. r.l.; CCRIS 6009; C16H13ClN2O; DEA No. 2765; Oprea1_126223; BSPBio_003279; KBioGR_001012; HSDB 3057; MLS000759402; D0899_SIGMA; D9900_SIGMA; DivK1c_000967; Ro 5-2807; Diazepam (JP15/USP/INN); Methyldiazepinone (pharmaceutical); S.A. R.L; Methyldiazepinone, pharmaceutical; CB 4261; CHEBI:49575; EINECS 207-122-5; KBio1_000967; KBio3_002780; WY-3467; CID3016; Diazepam [USAN:BAN:INN:JAN]; Diazepam [USAN:INN:BAN:JAN]; LA-111; NINDS_000967; NSC-77518; AIDS001617; NSC 169897; Wy 3467; AIDS-001617; NSC77518; BRN 0754371; LA 111; LS-122; NSC169897; ZINC00006427; DB00829; Ro 5-2805; IDI1_000967; 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; NCGC00178168-01; WLN: T67 GNV JN IHJ CG G1 KR; CPD000058398; SAM001246536; SMR000058398; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-; 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one; 7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine; 7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; C06948; D00293; 439-14-5; 5-24-04-00300 (Beilstein Handbook Reference); A3662/0155188; 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one; DZP; Dap; Pax; 11100-37-1; 53320-84-6; InChI=1/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H.. [ Warning Note: The above content needs verification ]

Rebranding as per the BNF as a Patent expires or a new formulation introduced having the same composition?. So subsequent New Trademarks for a Medicine allow Chemists Shelves to be restocked leading many to view such products as being fundamentally different from those being replaced. Its like the Passport Office allowing one to take on a different name at each renewal in promoting Identity theft leaving the Government to scratch its heads!. 

 

In terms of a refreshing soft drink a sweetner may have been added like Aspartame [ C14H18N2O5 ] or additive E951. It has the following synonyms:- 1-Methyl N-L-alpha-aspartyl-L-phenylalanate,   1-Methyl N-L-alpha-aspartyl-L-phenylalanine,   22839-47-0,   3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester,   3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester, stereoisomer,   3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid,   53906-69-7,   7421-84-3,   APM,   Asp-phe-ome,   Aspartam [INN-French],   Aspartame,   Aspartame (USAN),   Aspartame [USAN:BAN:INN],   Aspartame, L,L-alpha-,   Aspartamo [INN-Spanish],   Aspartamum [INN-Latin],   Aspartylphenylalanine methylster,   C11045,   Canderel,   CCRIS 5456,   D02381,   Dipeptide sweetener,   EINECS 245-261-3,   Equal,   HSDB 3915,   L-Aspartyl-L-phenylalanine methyl ester,   L-Phenylalanine, L-alpha-aspartyl-, 2-methyl ester,   L-Phenylalanine, N-L-alpha-aspartyl-, 1-methyl ester,   Methyl aspartylphenylalanate,   Methyl L-alpha-aspartyl-L-phenylalanate,   Methyl L-aspartyl-L-phenylalanine,   Methyl N-L-alpha-aspartyl-L-phenylalaninate,   N-L-alpha-Aspartyl-L-phenylalanine 1-methyl ester,   Nutrasweet,   SC 18862,   Succinamic acid, 3-amino-N-(alpha-carboxyphenethyl)-, N-methyl ester, stereoisomer,   Sweet dipeptide,   Tri-sweet .. [ Warning Note: The above content needs verification ]

 

On the matter of a drug named Seroxat [ Paxil in the U.S ] in an article dated April 2002 Mr. Alan Chandler, GlaxoSmithKline’s director of Corporate Media UK stated that "There is no scientific evidence that Seroxat leads to addiction and dependency……..”. In the Seroxat Patient Information Leaflet [ PIL ] ( revised Jan 2002 ) it states that “These Tablets are NOT ADDICTIVE”  ….”remember that you cannot become addicted to ‘Seroxat’”, and that the withdrawal symptoms some people experience when stopping paroxetine “are not common and (they) are not a sign of addiction”. In a warning to USA Doctors in Jan 2002  they were advised that “Paxil has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical dependence”. In a World Health Organisation [ WHO ] bulletin, Drug information ( 1998, 12, 3, 136-138) it states that “There is obviously some confusion about the concept of dependence … The simplist definition of drug dependence given by WHO is ‘a need for repeated doses of the drug to feel good or to avoid feeling bad’. The word “addiction” is undefined and the WHO’s Expert Committee on drug dependence has specifically asked that the word not be used, because its meaning is imprecise and uncertain. The European Medicines Evaluation Agency (EMEA) however recommended that, in the Summary of Product Characteristics, there should be "A statement that although withdrawal reactions may occur on stopping therapy, the available preclinical and clinical evidence does not suggest that SSRIs cause dependence.".

 

Its all very well Mr Chandler of GlaxoSmithKline’s and the EMEA saying that there is no scientific evidence that Seroxat leads to addiction and dependency……..” but there exists no scientific evidence either to suggest that addiction or dependency does not occur!. Obviously the results of Science take presidence over the REAL OUTCOMES as to the SUFFERING and SUICIDES caused but given that the focus is on Business and not Cemetaries it becomes easier to understand the minds of blinkered Scientific achievement through the phrase “The Patient died but the operation was a complete success”. 

 

 

 

My experience of Seroxat: In becoming mentally “burnt out” as a College Lecturer through New Labour’s efforts to Privatise Colleges whereby all my hours be condensed into a three day week I was prescribed Seroxate [ around 1997 ]. For the first few weeks, besides tingling finger tips and the sensation that someone was touching my face, my mind became imprisoned in wanting to be alone and concentrate on issues which lead me to become ill – repetition/reoccurance - none stop mental activity looping around yet now a zombie withdrawn into a mental and physical isolation. On many occasions I would simply get into my car and disappear for some 3 days – Why 3 days?. Being unplanned ventures I would always forget to take along my Seroxat Medication and by the 3rd day I would be that ill that I needed to seek a Hospital Emergency and Accident Ward. It felt as though I had just began taking the Medication again accept the tingling sensations were accompanied by the shakes, tears and a severe headache. How does one escape from oneself’s mental imprisonment I constantly quizzed night and day as the daily bad News provided by the Media became amplified in adding to my thoughts on how to escape from it all!. To stop breathing  seemed the only answer but I didn’t want to kill myself – how strange life had become in being trapped between the devil and Authority whom had “pickled my mind” into a jar like existence with no understanding as to my condition!. The eventual occurred in about 2000 but I cannot recall waking up in a Hospital after dying.  

 

To digest a headache tablet one does not generally keep taking more tablets once the headache has passed however with Seroxat [ a prescribed mind trance ( isolation – lock down outward ) and bodily influencing drug ] ADDICTION and DEPENDENCE is REAL. One become dependently addicted to it (1) Dependence - one knows by mid-afternoon that one has missed taking a tablet that morning as the fingers begin to tingle and the body begins to shake!. (2) Addiction – is about the mind KNOWING that it will become intolerable to function should medication be missed and so constant awareness as to the prior administration of the drug creates an addiction. It’s the reverse of alcohol addition in that one consumes it to “bring on” a known  good feeling effect whereas the continued taking of Seroxat  prevents the “bring on” of a bad feeling effect!.

 

Personally I wouldn’t give Seroxat to my dog to see it suffer but what was I to do?. To reduce the medication one becomes very ill and so one is prescribed a bigger dosage to re-establish a zombie like existence. I thus set about reducing the dosage myself by breaking tablets into two and putting up with the adverse bodily reactions. Then came the day when enough was enough – no more. Strange is life in now waking up to REALITY.  In being mentally DISPOSED over a long period of time it has allowed others to freely take everything away from me however such realizations have also made me become an OBSERVER in discovering how others are being abused.

 

 

Below I have included some History on paroxetine [ Seroxat / Paxil ] but note the date 1980 March and reference to “Hypnotic Drug for Human Use”

 

Seroxat [ Paxil in the U.S ]  History:-

1960’s Ferrosan[ A small Danish company ] was involved in VETERINARY medicine activities concerned with CNS ( Central Nervous System ) research headed by a Dr. Jorgen Buus-Lassen – A “Doctor of Veterinary Medicine”.

1975 Paroxetine (Seroxat / Paxil U.S) was first developed. Dr Buus Lassen's first paper on paroxetine was published

1977 Ferrosan patented the formula for the “Buus-Lassen compound” in 1977 under U.S. Patent #4,007,196

1980 Ferrosan licensed the #4,007,196 patent and its other “PHC-related technology” to SmithKline whom began manufacturing PHC in its Harlow plant in England.

1980’s Ferrosan and Beecham were beaten to production by the rival firm of Astra, whose SSRI zimelidine appeared in the mid-80s But when it was tested in the UK a few patients developed a serious auto-immune condition damaging peripheral nerves, and it was discontinued. The same fate befell a drug produced in France called indalpine, which was thought extremely effective until damage was detected to blood-cells.

1980 Ferrosan sold paroxetine to Beecham pharmaceuticals.

1980 March: Hypnotic Drug for Human Use.  PAXIL TRADEMARK applied for by (REGISTRANT) Boehringer Ingelheim G.m.b.H. limited joint stock company FED REP GERMANY Ingelheim am Rhine FED REP GERMANY 6507. Hypnotic Drug for Human Use. FIRST USE: 19800104. FIRST USE IN COMMERCE: 19800104. Serial Number: 73255881. Registration Number: 1170889. Registration Date: September 29, 1981. Attorney of Record: Blum, Kaplan, Friedman, Silberman & Bera. Cancellation Date: April 7, 1988.

Visit webpage: http://tess2.uspto.gov/bin/showfield?f=doc&state=abn0ie.2.16

1980 Dr. Jørgen Buus Lassen Managing Director of Ferrosan A/S´ research and development division, responsible for the expansion of all pre-clinical and clinical activities.

1980 FILING DATE March 28, 1980- PAXIL Registration Number 1170889 Registration Date September 29,

1981 September 29: Registration Date Registration Number 1170889. Owner (REGISTRANT) Boehringer Ingelheim G.m.b.H. limited joint stock company FED REP GERMANY Ingelheim am Rhine FED REP GERMANY 6507. Attorney of Record Blum, Kaplan, Friedman, Silberman & Bera.  

1986 FERROSAN ACQUIRED BY Novo Industri A/S [ now Novo Nordisk A/S ]

1987 Eli Lilley launched fluoxetine in 1987, and under its tradename of Prozac - it wasn't long before negative stories began appearing

1988 Dr. Jørgen Buus Lassen finishes as serving Managing Director of Ferrosan A/S´ research and development division,

1988 Cancellation Date FOR Boehringer Ingelheim G.m.b.H. limited joint stock company FED REP GERMANY Ingelheim am Rhine FED REP GERMANY 6507 of Serial Number 73255881 .

1989 Dr. Lassen becomes co-founder of NeuroSearch A/S as President and CEO.

1991 Seroxat [tradenames of Paroxetine ] launched in the UK, its first market and Paxil in the US.

1992 Paroxetine licensed as Seroxat in the United Kingdom. Marketers within SmithKline Beecham [ SKB ] coined the acronym SSRI. The name worked - too well. It was adopted for the entire group of compounds. In this way, Paxil made Prozac and Zoloft into SSRIs.

1992 Dec 29 FDA approves SKB’s Paxil’s application – Paxil now for sale in the U S Drug class: Antidepressant Chemical Formula: C19H20FNO3 Legal status: Prescription only. Habit forming? No!. Originally discovered: 1975, Ferrosan Denmark

1993 Paroxetine licensed as Paxil in the United States

1997 Dr. Jørgen Buus Lassen now a Board Member of Pharmexa.

1999 World Health Organisation published a study which placed Seroxat at the top of a list of drugs which doctors believe cause marked withdrawal problems, with twice as many complaints as the next drug

2000 GSK sales of Seroxat/ Paxil were valued at £1,550m, a 17 per cent increase on the previous year, and the drug ranks in one of GSK's top six performers alongside Avandia for diabetes and Flixotide for asthma. Part of this success is the way it has been aggressively marketed to doctors (and in the US, directly to patients).

2001 Beecham is now part of GSK, the world's second-largest pharmaceutical company, boasting a pre-tax profit of £6.2bn

2001 GSK were ordered to pay $6.4m to the family of Donald Schell, after a jury in Wyoming heard that he had killed his wife, daughter and granddaughter and then himself after two days on Seroxat.

2007 May 6th Sara Carlin, a graduate of St. Ignatius of Loyola Catholic Secondary School and an Ontario Scholar when she took her own life after being prescribed Seroxat